Please wait...

You selected inventions in category Biology

  • A Formulation for treating LeishmaniasisA Formulation for treating Leishmaniasis

      The technology is in form of a formulation that is effective in treating intracellular protozoan parasitic infections (especially Leishmaniasis) and overcoming the associated complications. The technology provides a sterol enriched mixed lamellarity amphotericin intercalating liposomes for targeted delivery of liposomal amphotericin B thereby reducing toxicities of amphotericin B. The liposomal formulation is sonicated before administration to increase the plasma half-life of the liposomal drug for facilitating better bio-distribution in the body. The formulation is sugar free and thus can be freely use by diabetics. The technology has been tested on the mice for tolerance study

      Full details Contact close
    • A herbal pesticideA herbal pesticide

        The present technology provides a sprayable biopesticidal composition comprising Photorhabdus luminescens for controlling and eradicating various agricultural pests. It is for the first time that the insecticidal activity of P. luminescens is used without its symbiotic carrier nematode. In the present technology the actively growing cells of P. luminescens are encapsulated in sodium alginate beads and examined for their ability to infect insect hosts. Several laboratory and field testing programme were carried out to evaluate and assess the product. Elaborative and extensive field trials were conducted to study the efficacy of the product on the serious pest of sugarcane. The results obtained from these experiments have given a clear indication that the product is very effective and is novel based on the bacterium Photorhabdus luminescence and the plant, bacterial and insect chitinase purified to greatest extent and stabilized for longer shelf life.

        Full details Contact close
      • A kit to diagnose Heart diseaseA kit to diagnose Heart disease

          The proposed technology suggests a heart disease diagnostics kit that uses multifractal analysis tests to produce an integrated, noninvasive diagnostic/prognostic approach for diagnosis of heart disease, prognostication, prediction of risk of sudden death, and prediction of response to therapy. Useful results from these tests can be made available in 15 minutes or less to several hours. A multifractal version of the ST alpha scaling coefficient and a multifractal version of the LT alpha offer additional useful information about cardiac disease. Researchers have also refined preexisting multifractal analytic methods to eliminate the confounding effect of skipped/abnormal/ectopic beats, frequently found in the general population and patients with cardiac disease.

          Full details Contact close
        • A Lipid-based Drug for Treating CancerA Lipid-based Drug for Treating Cancer

            The technology is in form of a “Lipid based drug” which is aimed at treating cancer by occluding the blood supply to the tumor region. The said drug when injected intra-tumorally cut off the blood supply to the tumor, causing it to basically starve and die because of a lack of blood, without leaving any side-effect on the patient body. This is for the first time ever a lipid-based drug is developed for cancer. The molecule developed is a naturally occurring lipid present in the body, is non –toxic, and has both direct and selective tumoricidal and anti-angiogenic actions.
            The angiography study performed on five patients who have been administered this drug clearly highlights its highly selective mode of action. The administered drug selectively occludes tumor-feeding vessels without having any significant side-effects on the adjoining tissues.
            The methods of administration of this drug:
            (a) To locate an artery which carries major blood supply to the neoplastic region and which is proximal to the neoplastic region
            (b) Intra-arterially injection of therapeutically effective amount of “Lipid-based drug” into the located artery

            Full details Contact close

              Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

              Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

              The main advantages of the offered drug are:
               confirmed ability to efficient bind of herpes simplex virus (HSV-1)
              and inhibit its replication in vitro,
               low-toxicity of the drug in vitro,
               the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

              The offered invention is subject of a patent application. Further research
              and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

              More information:
              PhD Klaudia Polakowska – Technology Transfer Officer
              phone. +48 12 663 3832, +48 519 329 129,

              Full details Contact close
            • A new drug for the prevention and treatment of human influenza A virus IAV human metapneumovirus hMPV and human rhinoviruses HRVA new drug for the prevention and treatment of...

                Potential drug: a modified polyallylamine derivative

                Application: prevention and treatment of human influenza A virus (IAV), human metapneumovirus (hMPV) and human rhinoviruses (HRV)

                Influenza is an acute infectious disease caused by viruses belonging to the Orthomyxoviridae family, and classified into three types: A, B and C. This classification is based on antigenic differences between the major virion proteins, e.g. M protein and nucleoprotein NP. These types differ in terms of epidemiological properties.

                Influenza A virus (IAV) causes acute and chronic respiratory infections. It is a major respiratory pathogen of humans and animals. A period of frequent influenza infections occurs each winter (seasonal flu, the highest incidence occurring
                in January/February). Only type A influenza virus causes epidemics and pandemics because of antigenic shift that is multiple changes in the various genome segments resulting from reassortment of different strains of the virus.

                According to the World Health Organization (WHO) infections with influenza
                and influenza-like viruses occur globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The most severe infections develop in children under two years of age, in the elderly aged 65 or older and in those with compromised immunity. WHO recommends vaccination against the influenza virus as the most effective way to prevent infections. On the other hand, because of a large variability of the virus, the difficulty in obtaining sufficient number of vaccines before the epidemic wave, and not always satisfactory efficacy of the vaccine and anti – influenza drugs, the disease still represents an important medical and epidemiological problem. Therefore, new effective drugs for the anti-influenza treatment are needed.

                The new invention of the Jagiellonian University, which is the subject
                of the proposed offer, discloses a new drug for the treatment of human A virus (IAV) infection.

                Human metapneumovirus (hMPV) was identified in 2001, however, it was proved that infections with this pathogen have occurred in the human population for
                at least 50 years now. It is the only known Pneumovirus which infects humans and causes both upper and lower respiratory tract infections. Respiratory infections caused by hMPV have been reported in patients of every age and gender,
                but children under 5 years are most likely to be susceptible to infections caused
                by hMPV. The clinical manifestations of hMPV disease are flu-like symptoms such
                as runny nose, cough, sore throat and high fever. The virus is widespread, and is found on all continents. Late winter and early spring is the epidemic peak of hMPV infections. More serious symptoms, including severe lower respiratory tract infections, are found mainly in young children and infants under 5 years
                of age, elderly individuals above 60 years of age, and immunocompromised patients, whereas immunocompetent adults present mostly flu-like illnesses or cold symptoms.
                So far, no other drug has been approved for inhibition and prevention
                of infections caused by hMPV. By 2012, the only drugs with broad spectrum
                of activity (such as ribavirin and immunoglobulins) have been used to treat very acute, severe hMPV infections of patients after lung transplantation. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of human metapneumovirus (hMPV) infection.

                The human rhinovirus (HRV) belongs to the smallest known viruses (their diameter does not exceed 30 nm). During the year, particularly in winter and spring, it causes infections of the upper respiratory tract with humans, appearing as the common cold. Rhinoviruses also cause otitis media, sinusitis and inflammations of the lower respiratory tract, including bronchi

                Full details Contact close
              • A New Method for Cheaper and Longer Lasting BioimplantsA New Method for Cheaper and Longer Lasting...

                  The technology is therefore aimed at addressing the various shortcomings associated with the existing implants thereby improving implant making processes. The present technology provides novel titanium based composite bioactive (biocompatible) material useful as prosthetic implant as against conventional processes where-in the bioactive phases, usually calcium phosphatic chemicals, is present on the surface of the bioinert Ti. The novel titanium based implant allows tissue growth deep into the composite as against the conventional Ti based surface-coated implants which enable only surface integration because of the presence of bioactive phase only on the surface allowing tissue growth only at the surface of the implant, limited to the thickness of the bioactive coated phase. The implant when implanted in place of a damaged bone, can locate itself securely at the implantation and enables through integration with the healthy bone, thus completely avoiding any possibility of the implant getting loosened. The Ti based biocompatible material is capable of extracting out biological HA from the body fluids hence it substitutes the need of synthetic HA. Titanium oxide and certain calcium phosphatic and chemicals, which get formed in the present invention, have the potential to precipitate out biological HA from body fluids. This fact is proved by immersing the implant in SBF (Simulated Body Fluids). In biological HA the sizes of individual particles are more uniform. In the context of longevity of the implant, it is better to have more amount of biological HA in the implant and reduce the amount of synthetic HATitanium base powders are mixed with powder precursors of calcium and phosphorus, blended, milled and compacted. These compacts when calcined at 600-1200°C under various atmospheres form in situ calcium-phosphatic bioactive phases distributed uniformly in bioinert titanium phases. The calcined compacts are crushed, compacted to shape and vacuum sintered at 1000-1250°C to obtain appropriate interconnected porosity and strength. Immersion of the biocomposite in simulated body fluids, led to precipitation of bioactive phases like calcium hydroxyapatite, tricalcium phosphate, sodium calcium phosphate and calcium hydrogen phosphates on the surface, indicating biocompatibility of the implantable material having required interconnected porosity for facilitating tissue growth. The composite material thus developed by such process is noncytotoxic, has adequate corrosion properties, mechanical strength and can be used for orthopedic and other implants.The bioactive phases are not directly added to Ti, but added in the form of salts of calcium and phosphorus which during processing, convert into different bioactive phases within the bio inert Ti in situ - thereby ensuring proximity of the bioactive phases thus formed with the Ti phase. In vitro-cytotoxicity tests were performed and it was confirmed that the biocomposite produced by the process of this technology is non- cytotoxic.

                  Full details Contact close
                • A New Recombinant Mouse-Human Antibody against Hepatitis-BA New Recombinant Mouse-Human Antibody against...

                    The technology suggests a process to generate a recombinant mouse-human chimeric antibody fragment, against Hepatitis B surface antigen. The process is consist of the below given steps.
                    1. Amplification of the variable region genes (VH and VL) of the anti-HBs mouse monoclonal 5S by reverse transcription (RT) followed by polymerase chain reaction (PCR). RNA isolated from 5S hybridoma was used as the source of these two genes.

                    2. Amplification of constant region of human kappa chain (Ck) and first constant region of human IgGl heavy chain (CH1) by reverse transcription (RT) followed by polymerase chain reaction (PCR). RNA isolated from human peripheral blood lymphocytes (PBLs) was used as the source of these two genes.
                    3. Mouse VL and human CK were linked by overlap PCR to generate chimeric light chain. Similarly mouse VH and CH1 were linked by overlap PCR to generate chimeric Fab.
                    4. Both of these chimeric antibody genes were cloned into a bicistronic bacterial expression vector (pCOMB3H, Scripps Research Institute, La Zola, USA) to express the chimeric Fab in the periplasm of E.coli (XLl-blue).
                    5. Recombinant clone was cultured in suitable medium and cell extract was prepared by the conventional method.
                    6. The recombinant chimeric antibody was purified by affinity chromatography using Protein G.
                    This recombinant molecule was generated by fusing variable region genes (Variable Heavy and Variable Low) of an anti-HBsAg mouse antibody 5S and constant region genes of human (CHl region of human IgGl and the CL region of human kappa chain).

                    Full details Contact close